Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 16 01 2020
revised: 10 03 2020
accepted: 23 03 2020
pubmed: 30 3 2020
medline: 15 9 2021
entrez: 30 3 2020
Statut: ppublish

Résumé

The genomic underpinning of clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer is unclear. In patients with metastatic castration-sensitive prostate cancer at a tertiary referral center, clinical-grade targeted tumor sequencing was performed to quantify tumor DNA copy number alterations and alterations in predefined oncogenic signaling pathways. Disease volume was classified as high volume (≥4 bone metastases or visceral metastases) versus low volume. Among 424 patients (88% white), 213 (50%) had high-volume disease and 211 (50%) had low-volume disease, 275 (65%) had This study identified genomic features associated with prognosis in metastatic castration-sensitive disease that may aid in molecular classification and treatment selection.

Identifiants

pubmed: 32220891
pii: 1078-0432.CCR-20-0168
doi: 10.1158/1078-0432.CCR-20-0168
pmc: PMC7334067
mid: NIHMS1580358
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

3230-3238

Subventions

Organisme : NCI NIH HHS
ID : P01 CA228696
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Cancer Cell. 2012 Sep 11;22(3):373-88
pubmed: 22975379
N Engl J Med. 1989 Aug 17;321(7):419-24
pubmed: 2503724
Cancer Cell. 2018 Dec 10;34(6):996-1011.e8
pubmed: 30537516
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
J Clin Invest. 2020 Apr 1;130(4):1743-1751
pubmed: 31874108
Urol Oncol. 2017 Aug;35(8):535
pubmed: 28623072
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Prostate. 2018 Sep;78(12):889-895
pubmed: 29707790
Eur Urol. 2019 Jul;76(1):89-97
pubmed: 30553611
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
Am J Epidemiol. 2005 Aug 1;162(3):199-200
pubmed: 15987728
Ann Oncol. 2018 Feb 1;29(2):352-360
pubmed: 29069303
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
J Clin Oncol. 2019 Nov 10;37(32):2961-2967
pubmed: 31498754
Eur Urol. 2018 Jun;73(6):847-855
pubmed: 29475737
Clin Cancer Res. 2017 Nov 15;23(22):6802-6811
pubmed: 28842510
Clin Genitourin Cancer. 2017 Aug 31;:
pubmed: 28899723
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395
pubmed: 31085648
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Ann Oncol. 2019 Dec 1;30(12):1992-2003
pubmed: 31560068
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Eur Urol. 2019 Nov;76(5):562-571
pubmed: 30928160
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Eur Urol. 2019 Aug;76(2):137-139
pubmed: 31031048
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Elife. 2018 Sep 04;7:
pubmed: 30178746
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Eur Urol. 2016 Aug;70(2):256-62
pubmed: 26610858
Nat Genet. 2012 May 20;44(6):685-9
pubmed: 22610119
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821

Auteurs

Konrad H Stopsack (KH)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Subhiksha Nandakumar (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Andreas G Wibmer (AG)

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

Samuel Haywood (S)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Emily S Weg (ES)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Ethan S Barnett (ES)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Chloe J Kim (CJ)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Emily A Carbone (EA)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Samantha E Vasselman (SE)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Bastien Nguyen (B)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Melanie A Hullings (MA)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Howard I Scher (HI)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Michael J Morris (MJ)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

David B Solit (DB)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Nikolaus Schultz (N)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Philip W Kantoff (PW)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. abidam@mskcc.org kantoff@mskcc.org.
Weill Cornell Medical College, New York, New York.

Wassim Abida (W)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. abidam@mskcc.org kantoff@mskcc.org.
Weill Cornell Medical College, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH